Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.50 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8985304 | 0.88 | PTGS2 (0.55) | PTGS2PTGS1MAPK14KDM4EMT-CO1 | |
| SCHEMBL8985490 | 0.88 | PTGS2 (0.67) | PTGS2PTGS1MAPK14KDM4EMT-CO1 | |
| SCHEMBL8985205 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1MAPK14KDM4EMT-CO1 | |
| SCHEMBL7617599 | 0.83 | PTGS2 (0.64) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL3246286 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL8985337 | 0.80 | PTGS2 (0.52) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL8985408 | 0.80 | PTGS2 (0.52) | PTGS2PTGS1MAPK14KDM4EMT-CO1 | |
| SCHEMBL8985321 | 0.77 | MAPK14 (0.68) | PTGS2PTGS1MAPK14KDM4EMT-CO1 | |
| SCHEMBL8985212 | 0.77 | PTGS2 (0.52) | PTGS2PTGS1MAPK14KDM4EMT-CO1 | |
| SCHEMBL2349058 | 0.77 | CA12 (0.66) | PTGS2PTGS1KDM4ECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| US-20010016595-A1 | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | MERCK FROSST CANADA INC./MERCK FROSST CANADA & CO. | 2001-08-23 | — | — | US | claimed |
| EP-0980866-A2 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | Merck Frosst Canada & Co. (CA) | 2000-02-23 | — | — | EP | claimed |
| JP-2977137-B2 | — | — | 1999-11-10 | — | — | JP | claimed |
| US-5840746-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1998-11-24 | — | — | US | claimed |
| EP-0822190-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1998-02-04 | — | — | EP | claimed |
| EP-0754687-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1997-01-22 | — | — | EP | claimed |
| CN-1125944-A | Phenyl heterocyclic compounds useful as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC (CA) | 1996-07-03 | — | — | CN | claimed |
| EP-0705254-A1 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-04-10 | — | — | EP | claimed |
| WO-1995000501-A2 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-01-05 | — | — | WO | claimed |
| EP-1146789-A4 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7041694-B1 | Cyclooxygenase-2 inhibition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| CN-1129576-C | Phenyl heterocyclic compounds useful as cyclooxygenase-2 inhibitors | MCFROST CANADA CO (CA) | 2003-12-03 | — | — | CN | disclosed |
| US-6486194-B2 | ALZHEIMER'S DISEASE | MERCK FROSST CANADA, INC. (CA) | 2002-11-26 | — | — | US | disclosed |
| US-6486203-B1 | Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors | CORNELL RESEARCH FOUNDATION, INC. | 2002-11-26 | — | — | US | disclosed |
| CN-1125944-A | Phenyl heterocyclic compounds useful as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC (CA) | 1996-07-03 | — | — | CN | disclosed |
| EP-0705254-A1 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-04-10 | — | — | EP | disclosed |
| US-5474995-A | Nonsteroidal, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1995-12-12 | — | — | US | disclosed |
| WO-1995018799-A1 | PHENYL HETEROCYCLES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995000501-A2 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016595-A1 | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | PTGS1, PTGES2, PTGS2 | PTGS2 3/4885PTGS1 1/4885MAPK14 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.